Ashish Kumar Kakkar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1325889/publications.pdf

Version: 2024-02-01

687363 526287 41 786 13 27 citations h-index g-index papers 41 41 41 1514 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Deciphering the COVIDâ€19 cytokine storm: Systematic review and metaâ€analysis. European Journal of Clinical Investigation, 2021, 51, e13429.	3.4	176
2	Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls. Tuberculosis, 2014, 94, 357-362.	1.9	95
3	Drug treatment of obesity: Current status and future prospects. European Journal of Internal Medicine, 2015, 26, 89-94.	2.2	85
4	Management of Parkinson×3s disease: Current and future pharmacotherapy. European Journal of Pharmacology, 2015, 750, 74-81.	3.5	68
5	Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems. Frontiers in Public Health, 2020, 8, 140.	2.7	51
6	The Evolving Drug Development Landscape: From Blockbusters to Niche Busters in the Orphan Drug Space. Drug Development Research, 2014, 75, 231-234.	2.9	42
7	Effect of lamotrigine, levetiracetam & topiramate on neurobehavioural parameters & oxidative stress in comparison with valproate in rats. Indian Journal of Medical Research, 2016, 144, 104.	1.0	27
8	Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. Expert Review of Anti-Infective Therapy, 2020, 18, 997-1003.	4.4	22
9	Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions. International Journal of Risk and Safety in Medicine, 2018, 30, 33-44.	0.6	21
10	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. European Journal of Pharmacology, 2021, 890, 173717.	3.5	18
11	Effect of antiepileptic therapy on trace elements status in Indian population in a tertiary care hospital from northern India: A cross sectional study. Epilepsy Research, 2014, 108, 917-927.	1.6	17
12	Old wines in new bottles: Repurposing opportunities for Parkinson's disease. European Journal of Pharmacology, 2018, 830, 115-127.	3.5	15
13	Statin use and safety concerns: an overview of the past, present, and the future. Expert Opinion on Drug Safety, 2020, 19, 1011-1024.	2.4	15
14	Patent cliff mitigation strategies: giving new life to blockbusters. Expert Opinion on Therapeutic Patents, 2015, 25, 1353-1359.	5.0	13
15	mHealth technologies in clinical trials: Opportunities and challenges. Indian Journal of Pharmacology, 2018, 50, 105.	0.7	12
16	Ensuring access to †access' antibiotics: an imminent consideration for sustainable antimicrobial stewardship in the developing world. Infectious Diseases, 2019, 51, 395-398.	2.8	10
17	Comparison of body composition in persons with epilepsy on conventional & mp; new antiepileptic drugs. Indian Journal of Medical Research, 2016, 143, 323.	1.0	10
18	Statin related adverse effects and patient education: a study from resource limited settings. Acta Cardiologica, 2018, 73, 393-401.	0.9	9

#	Article	IF	CITATIONS
19	Decoding the Roadmap for Capacity Building of Pharmacology Academicians in Catering to Drug Information Center Services in a Developing Country. Journal of Pharmacy Technology, 2019, 35, 146-154.	1.0	8
20	Knowledge, attitude, and practice survey on antimicrobial use and resistance among Indian clinicians: A multicentric, cross-sectional study. Perspectives in Clinical Research, 2022, 13, 99.	1.0	8
21	The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor. Current Clinical Pharmacology, 2016, 11, 88-94.	0.6	7
22	Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges. Expert Review of Neurotherapeutics, 2021, 21, 35-43.	2.8	6
23	Factors affecting choice of future specialty among medical students. North American Journal of Medical Sciences, 2014, 6, 181.	1.7	5
24	Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation. Journal of Oncology Pharmacy Practice, 2015, 21, 358-363.	0.9	5
25	Cefazolin Shortages in the Developing World: The Same, But Different Too. Clinical Infectious Diseases, 2021, 72, 1293-1295.	5.8	5
26	Assessment of Appropriateness of Antimicrobial Therapy in Resource-Constrained Settings: Development and Piloting of a Novel Tool—AmRAT. Antibiotics, 2021, 10, 200.	3.7	4
27	Current Issues With the Use of Bedaquiline. Annals of Pharmacotherapy, 2014, 48, 666-666.	1.9	3
28	Methodological Characteristics of Clinical Trials: Impact of Mandatory Trial Registration. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 131-141.	2.1	3
29	Developing a latent class analysis model to identify at-risk populations among people using medicine without prescription. Expert Review of Clinical Pharmacology, 2020, 13, 1411-1422.	3.1	3
30	Efficacy of anifrolumab in systemic lupus erythematosus: a critical analysis of the TULIP trials. Lupus, 2020, 29, 1002-1003.	1.6	3
31	Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs. Expert Opinion on Therapeutic Patents, 2021, 31, 189-192.	5.0	3
32	Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?. Expert Review of Clinical Pharmacology, 2021, 14, 315-322.	3.1	3
33	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. Expert Review of Anti-Infective Therapy, 2021, 19, 1331-1339.	4.4	3
34	Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study. Indian Journal of Medical Research, 2017, 146, 468-475.	1.0	3
35	Satisfaction With Statin Treatment Among Adult Coronary Artery Disease Patients: An Experience From a Resource-Constrained Setting. Heart Lung and Circulation, 2019, 28, 1788-1794.	0.4	2
36	Impact of pharmaceutical price controls on the cost of cardiovascular drugs: does essentiality matter?. Expert Review of Clinical Pharmacology, 2020, 13, 797-806.	3.1	2

3

#	Article	IF	CITATIONS
37	Posttrial Access to Medical Interventions: Intricacies, Challenges, and Solutions. International Journal of Applied & Basic Medical Research, 2019, 9, 3-8.	0.5	2
38	India Puts Informed Consent on Camera. Science, 2014, 344, 150-151.	12.6	1
39	Population Pharmacokinetics of Hydroxychloroquine Sulphate in Healthcare Workers Given for Prophylaxis Against Corona Virus Disease 2019 (COVIDâ€19) in India. Journal of Clinical Pharmacology, 0,	2.0	1
40	GLP-1 receptor agonists and the risk of colorectal cancer. Medical Hypotheses, 2014, 82, 796.	1.5	0
41	Statins-induced hepatotoxicity: still more questions than answers. Expert Opinion on Drug Safety, 2020, 19, 1653-1654.	2.4	0